Dyne Therapeutics (NASDAQ:DYN) Trading 7% Higher – Should You Buy?

Posted by Brenda Bartman on Jun 17th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) was up 7% during trading on Wednesday . The stock traded as high as $19.39 and last traded at $19.3330. Approximately 114,684 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 1,923,842 shares. The stock had previously closed at $18.07.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DYN shares. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Sanford C. Bernstein upped their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

View Our Latest Stock Report on Dyne Therapeutics

Dyne Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The stock’s 50 day simple moving average is $18.25 and its two-hundred day simple moving average is $18.12. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of -6.27 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the company posted ($1.05) EPS. On average, analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Erick Lucera sold 1,448 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $26,585.28. Following the sale, the chief financial officer owned 123,925 shares of the company’s stock, valued at $2,275,263. The trade was a 1.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares in the company, valued at approximately $144,749.16. This represents a 91.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have acquired 9,000 shares of company stock worth $156,800 and have sold 1,559,462 shares worth $29,814,746. Corporate insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Creative Planning boosted its stake in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the 1st quarter valued at $26,000. Caxton Associates LLP boosted its stake in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Dyne Therapeutics by 9.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after buying an additional 2,108 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.